Your browser doesn't support javascript.
loading
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer.
Lheureux, Stephanie; Matei, Daniela E; Konstantinopoulos, Panagiotis A; Wang, Ben X; Gadalla, Ramy; Block, Matthew S; Jewell, Andrea; Gaillard, Stephanie L; McHale, Michael; McCourt, Carolyn; Temkin, Sarah; Girda, Eugenia; Backes, Floor J; Werner, Theresa L; Duska, Linda; Kehoe, Siobhan; Colombo, Ilaria; Wang, Lisa; Li, Xuan; Wildman, Rachel; Soleimani, Shirin; Lien, Scott; Wright, John; Pugh, Trevor; Ohashi, Pamela S; Brooks, David G; Fleming, Gini F.
Afiliación
  • Lheureux S; Drug Development Program, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada stephanie.lheureux@uhn.ca.
  • Matei DE; Department of Obstetrics and Gynecology, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Illinois, USA.
  • Konstantinopoulos PA; Department of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Wang BX; Immune Profiling Team - Tumor Immunotherapy Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Gadalla R; Immune Profiling Team - Tumor Immunotherapy Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Block MS; Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.
  • Jewell A; Department of Gynecologic Oncology, University of Kansas Medical Center, Kansas City, Kansas, USA.
  • Gaillard SL; Department of Gynecology and Obstetrics, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
  • McHale M; Department of Obstetrics and Gynecology, Moores Cancer Centre, UC San Diego Health, La Jolla, California, USA.
  • McCourt C; Department of Gynecology Oncology, Washington University School of Medicine, St Louis, Missouri, USA.
  • Temkin S; Department of Gynecology Oncology, Virginia Commonwealth University, Richmond, Virginia, USA.
  • Girda E; Department of Gynecology Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
  • Backes FJ; Department of Gynecologic Oncology, Ohio State University, Columbus, Ohio, USA.
  • Werner TL; Division of Oncology, Department of Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.
  • Duska L; Department of Gynecology Oncology, University of Virginia, Charlottesville, Virginia, USA.
  • Kehoe S; Department of Gynecology Oncology, NYU Langone, New York City, New York, USA.
  • Colombo I; Drug Development Program, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Wang L; Department of Statistics, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Li X; Department of Statistics, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Wildman R; Drug Development Program, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Soleimani S; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
  • Lien S; Cancer Genomics Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Wright J; Drug Development Program, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Pugh T; Department of Immunology, University of Toronto, Toronto, Ontario, Canada.
  • Ohashi PS; Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland, USA.
  • Brooks DG; Cancer Genomics Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Fleming GF; Department of Immunology, University of Toronto, Toronto, Ontario, Canada.
J Immunother Cancer ; 10(3)2022 03.
Article en En | MEDLINE | ID: mdl-35288469
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Endometriales / Nivolumab Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Female / Humans Idioma: En Revista: J Immunother Cancer Año: 2022 Tipo del documento: Article País de afiliación: Canadá
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Endometriales / Nivolumab Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Female / Humans Idioma: En Revista: J Immunother Cancer Año: 2022 Tipo del documento: Article País de afiliación: Canadá